Výsledky vyhledávání - "Jean-Baptiste Fau"

Akademický článek

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

Autor: Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara, Hirotaka Kazama, Jean‐Baptiste Fau, Dorothée Semiond, Christine Veyrat‐Follet

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1846-1858 (2023)

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of s

Externí odkaz: https://doaj.org/article/daa28da7c7994013bf748c2247ab7421

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

Autor: Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai, Claire Brillac, Jean‐Baptiste Fau, Christine Veyrat‐Follet, Marie‐Laure Risse, Helgi van deVelde, Dorothée Semiond, Laurent Nguyen

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)

Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with rela

Externí odkaz: https://doaj.org/article/af2cc48054174339a0403cbbf840ec73

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Autor: Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 649-658 (2020)

Isatuximab, a monoclonal antibody (mAb) of immunoglobulin G (IgG) isotype, specifically targets the cluster of differentiation 38 antigen overexpressed in malignant plasma cells. Isatuximab is used to treat multiple myeloma (MM), characterized by the

Externí odkaz: https://doaj.org/article/0b977e74df2045d28990c4247039121a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Autor: Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)

Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini

Externí odkaz: https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. 11:766-777

Isatuximab is an approved anti-CD38 monoclonal antibody with multiple antitumor modes of action. An exposure-response (E-R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f2c0db9d6c587cf43463e77fd49629
https://doi.org/10.1002/psp4.12789

Zobrazit plný text záznamu

Plný text ve formátu HTML

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

Autor: Nadia Gaudel, Dorothée Semiond, Hoai-Thu Thai, Helgi van de Velde, Jean-Baptiste Fau, Geraldine Ayral, Christine Veyrat-Follet, Marc Cerou, Bernard Sebastien

Publikováno v: British Journal of Clinical Pharmacology. 88:2052-2064

Aims Addition of isatuximab to pomalidomide/dexamethasone (Pd) significantly improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). We aimed to characterize the relationship between serum M-protein kine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cd516ab66a9b269559399607b5904e
https://doi.org/10.1111/bcp.15123

Zobrazit plný text záznamu

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

Autor: Marie-Laure Risse, Raouf El-Cheikh, Christine Veyrat-Follet, Laurent Nguyen, Jean-Baptiste Fau, Kimiko Koiwai, Hoai-Thu Thai, Claire Brillac, Dorothée Semiond, Helgi van de Velde

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)
CPT: Pharmacometrics & Systems Pharmacology

This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a997ea428917d8421071c0e38a2a3e3
https://doaj.org/article/af2cc48054174339a0403cbbf840ec73

Zobrazit plný text záznamu

Plný text ve formátu HTML

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Autor: Frank Campana, Claire Brillac, Laurent Nguyen, Dorothée Semiond, Jean-Baptiste Fau, Nathalie Mace, Kimiko Koiwai, Raouf El-Cheikh

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 649-658 (2020)
CPT: Pharmacometrics & Systems Pharmacology

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b98ba770f1c9d065062922141573327
https://doaj.org/article/0b977e74df2045d28990c4247039121a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Autor: Helgi van de Velde, Frank Campana, Claire Brillac, Kimiko Koiwai, Jean Baptiste Fau, Fatiha Rachedi, Christine Veyrat-Follet, Dorothée Semiond, Hoai-Thu Thai, Raouf El-Cheikh, Nadia Gaudel-Dedieu, Li Liu, Bernard Sebastien, Laurent Nguyen

Publikováno v: Blood. 134:1897-1897

Background: Isatuximab (Isa) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement. Exposure-Response (E-R) analysis and disease modelling of tumor burden w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::898280446b5a0ffc7c8a5b47b4021889
https://doi.org/10.1182/blood-2019-128875

Zobrazit plný text záznamu

Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis

Autor: Sue Cheng, François Donat, Pierre Cortez, Ger-Jan Sanderink, Marc Trellu, Emmanuelle Boëlle, Isabelle Paty, Jean-Baptiste Fau

Publikováno v: British Journal of Clinical Pharmacology. 75:1255-1264

Aim To assess the bioequipotency of equimolar doses of idraparinux (2.5 mg) and idrabiotaparinux (3.0 mg). Method In a phase I study, 48 healthy male volunteers were randomized to a single subcutaneous injection of idrabiotaparinux or idraparinux, fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::532e3040b1060ee1bbc7a57898ea3567
https://doi.org/10.1111/bcp.12009

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání